Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 218 posts found.

jardiance-web

Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure

April 20, 2016
Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly

Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …

News
eli_lilly_logo

Eli Lilly drops development of diabetes drug in Phase III

April 19, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial

US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …

News
eli_lilly_logo

Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump

April 7, 2016
Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis

Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …

News
manufacturing

Sun to cut jobs in Irish facility closure; Lilly announce further investment in the country

April 6, 2016
Manufacturing and Production, Research and Development Eli Lilly, Ireland, Kinsale, Sun Pharma, cashel, investment, lilly

There was mixed news for pharmaceutical manufacturing in Ireland as Sun Pharma announced its decision to close its facility based …

News
eli_lilly

Lilly’s RA drug baricitinib meets Phase III goals

March 31, 2016
Research and Development Eli Lilly, Incyte, rheumatoid arthritis

Eli Lilly and Incyte have announced the publication of detailed Phase III trial results from a study of their biologic …

News
eli_lilly

FDA approves Lilly’s plaque psoriasis drug Taltz

March 23, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …

News
eli_lilly

Lilly changes Alzheimer’s trial endpoint – shares fall

March 16, 2016
Research and Development Alzheimer's disease, Eli Lilly, solanezumab

Shares in Eli Lilly fell more than 4% yesterday when it announced it was changing the primary endpoint of a closely-watched …

News
adocia_lilly

Adocia and Lilly report positive early results for ultra-rapid insulin

March 15, 2016
Manufacturing and Production, Research and Development Adocia, BioChaperone Lispro, Eli Lilly, insulinm

Eli Lilly and development partner Adocia have announced today positive topline results from a Phase 1b clinical trial of ultra-rapid …

News
eli_lilly

Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials

March 7, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis

Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …

News
eli_lilly

CHMP recommends Lilly psoriasis drug for approval

February 29, 2016
Research and Development Eli Lilly, Taltz, psoriasis

Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

News
eli_lilly

European Commission approves Lilly’s Portrazza for NSCLC

February 24, 2016
Research and Development Eli Lilly, Portrazza

The European Commission has approved Eli Lilly’s Portrazza (necitumumab), in combination with gemcitabine and cisplatin chemotherapy, as a first-line treatment …

News
eli_lilly

Lilly suffers damaging Alimta patent blow

February 15, 2016
Manufacturing and Production, Sales and Marketing Actavis, Alimta, Allergan, Eli Lilly, pemetrexed

Eli Lilly says it plans to appeal a UK High Court’s verdict that could imminently open its blockbuster lung cancer …

News
fda

Biosimilars: Can the US catch up in 2016?

February 12, 2016
Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars

What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …

Feature
Jardiance

FDA reviews Jardiance as cardiovascular diabetes treatment

January 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance

The FDA has accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for their diabetes drug Jardiance to be …

News
eli_lilly_logo

Lilly awaits FDA review of new arthritis treatment

January 20, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis

Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025